| Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency (NCT06754423) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-06-24 |
| Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (NCT05063994) | Neurocrine UK Limited | 2022-05-24 |
| Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia (NCT05299554) | Immedica Pharma AB | 2022-04-01 |
| A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH (NCT05128942) | Spruce Biosciences | 2021-12-10 |
| Gonadal Changes In Congenital Adrenal Hyperplasia Patients (NCT04903587) | Ain Shams University | 2021-10-01 |
| A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181]) (NCT05101902) | Adrenas Therapeutics Inc | 2021-07-01 |
| A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) (NCT04783181) | Adrenas Therapeutics Inc | 2021-07-01 |
| Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) (NCT04806451) | Neurocrine Biosciences | 2021-06-25 |
| China Adrenal Disease Registry (NCT04890444) | Shanghai Jiao Tong University School of Medicine | 2021-06-01 |
| A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH (NCT04544410) | Spruce Biosciences | 2021-02-22 |
| Retrospective Multicentre Study on the Impact of Neonatal Screening for Congenital Adrenal Hyperplasia in Italy (NCT06728748) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2020-10-23 |
| Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency (NCT04536662) | Shanghai Jiao Tong University School of Medicine | 2020-10-01 |
| Effects and Importance of Epinephrine/Adrenalin Deficiency in CAH (NCT05162950) | Region Stockholm | 2020-09-01 |
| A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH (NCT04457336) | Spruce Biosciences | 2020-08-26 |
| Final Height in Patients With CAH (NCT04293133) | Ain Shams University | 2020-03-11 |
| Linear Growth of Children With Congenital Adrenal Hyperplasia (NCT04087148) | Assiut University | 2019-09-24 |
| Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia (NCT03718234) | University of Minnesota | 2019-01-01 |
| Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (NCT03532022) | Neurocrine UK Limited | 2018-10-04 |
| GROWing Up With Rare GENEtic Syndromes (NCT04463316) | dr. Laura C. G. de Graaff-Herder | 2018-10-01 |
| Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia (NCT03687242) | Spruce Biosciences | 2018-09-06 |
| Nevanimibe HCl for the Treatment of Classic CAH (NCT03669549) | Millendo Therapeutics US, Inc. | 2018-07-11 |
| Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 (NCT02574910) | University of Texas Southwestern Medical Center | 2017-08-01 |
| Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (NCT03257462) | Spruce Biosciences | 2017-07-12 |
| Surgical Evaluation of Using the Prepuce in Feminizing Genitoplasty (NCT03897504) | Kasr El Aini Hospital | 2017-03-01 |
| Prenatal Dex Study (NCT02795871) | Hospices Civils de Lyon | 2016-10-04 |
| Dynamic Hormone Diagnostics in Endocrine Disease (NCT02934399) | Haukeland University Hospital | 2016-10-01 |
| A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH (NCT03062280) | Neurocrine UK Limited | 2016-08-18 |
| Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment (NCT03760835) | Federico II University | 2016-08-11 |
| A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia (NCT02804178) | Millendo Therapeutics, Inc. | 2016-05-18 |
| Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia (NCT02716818) | Neurocrine UK Limited | 2016-02-22 |
| Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (NCT02349503) | Neurocrine Biosciences | 2015-02-01 |
| Decision Support for Parents Receiving Information About Child's Rare Disease (NCT01875640) | University of Michigan | 2013-06-01 |
| Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH (NCT01735617) | Neurocrine UK Limited | 2012-12-01 |
| COrticosteroid in Congenital Adrenal Hyperplasia (NCT02552251) | University Hospital, Caen | 2012-08-01 |
| Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (NCT01807364) | Assistance Publique - Hôpitaux de Paris | 2011-05-01 |
| A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations (NCT03051893) | Neurocrine UK Limited | 2011-02-01 |
| Adult Height Prediction in Congenital Adrenal Hyperplasia (NCT03162159) | Hospices Civils de Lyon | 2010-09-01 |
| An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone (NCT03019614) | Neurocrine UK Limited | 2010-03-01 |
| Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia (NCT00519818) | Neurocrine UK Limited | 2007-08-01 |
| Qualitative Research on Women With Congenital Adrenal Hyperplasia (NCT00559078) | Lehigh University | 2007-07-01 |
| Gene Polymorphisms Influencing Steroid Synthesis and Action (NCT00485186) | University Hospital Schleswig-Holstein | 2007-06-01 |
| Study of UK Adults With Congenital Adrenal Hyperplasia. (NCT00749593) | Sheffield Teaching Hospitals NHS Foundation Trust | 2004-08-01 |
| Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia (NCT00011791) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2001-02-22 |
| Effects of Pioglitazone in Congenital Adrenal Hyperplasia (NCT00151710) | Radboud University Medical Center | |
| Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets (NCT00000102) | National Center for Research Resources (NCRR) | |